Last reviewed · How we verify

Planipart — Competitive Intelligence Brief

Planipart (CLENBUTEROL) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: clenbuterol. Area: Respiratory.

marketed clenbuterol 5-hydroxytryptamine receptor 1A, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Planipart (CLENBUTEROL).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Planipart TARGET CLENBUTEROL marketed clenbuterol 5-hydroxytryptamine receptor 1A, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Bystolic nebivolol Allergan marketed 5-hydroxytryptamine receptor 1A, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (clenbuterol class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Planipart — Competitive Intelligence Brief. https://druglandscape.com/ci/clenbuterol. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: